Effect of Inspiratory Muscle Training on Diaphragm and Ab-dominal Wall Muscle Thickness With Fatty Liver Density in Elderly Women: A Randomized Controlled Trial
IMT AND ELDERL
2 other identifiers
interventional
26
1 country
1
Brief Summary
Background: Post-menopausal estrogen decline is considered a contributing factor to sarcopenia, and inspiratory muscle training (IMT) may provide benefits in this demo-graphic. This study examined the impact of a four-week IMT program on diaphragm thickness, abdominal wall muscle thickness (AWMT; transversus abdominis, internal oblique, and external oblique), and liver fat percentage in healthy elderly women. Methods: Twenty-six women aged 60-80 years were randomly assigned to an IMT group (n = 13) or a control group (n = 13). The IMT group used the PowerBreathe® Classic device at 40% of maximal inspiratory pressure (MIP), with weekly increments of 10%. Training was performed twice daily, five days per week, with 30 breathing cycles per session (60 per day). The control group maintained their usual routines. AWMT, diaphragm thickness (DT), and fatty liver density (FLD) were measured by a radiologist before and after the intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 5, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 5, 2025
CompletedFirst Submitted
Initial submission to the registry
August 28, 2025
CompletedFirst Posted
Study publicly available on registry
September 11, 2025
CompletedSeptember 18, 2025
September 1, 2025
1 month
August 28, 2025
September 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
pre-training
Assessments were performed for all participants in both groups 4 weeks before and after treatment. These parameters were assessed using pre- and post-test measurements and compared between the IMT group and the control group Diaphragm Thickness (DT) * Mid-diaphragm thickness (MDT) * Posterior diaphragm thickness (PDT)
4 week
pre-training
Assessments were performed for all participants in both groups 4 weeks before and after treatment. These parameters were assessed using pre- and post-test measurements and compared between the IMT group and the control group -Fatty Liver Density (FLD)
4 Week
pre-training
Assessments were performed for all participants in both groups 4 weeks before and after treatment. These parameters were assessed using pre- and post-test measurements and compared between the IMT group and the control group Abdominal Wall Muscle Thickness (AWMT) * Right abdominal wall muscle thickness (RAWMT) * Left abdominal wall muscle thickness (LAWMT)
4 week
Study Arms (2)
Inspiratory muscle training
EXPERIMENTALInspiratory muscle training group (IMT n:13) IMT was performed using the POWERbreathe® device (POWER® Breathe Classic, IMT Technologies Ltd., Birmingham, UK). The POWERbreathe® device is a pressure-threshold IMT device that provides resistance during inhalation. The user breathes in through a mouthpiece against an adjustable spring-loaded valve, which opens only when the inspiratory pressure exceeds the set threshold, thereby strengthening the inspiratory muscles over time (Kowalski \& Klusiewicz, 2023). Following a one-week familiarization period, the IMT protocol was performed twice daily (morning and evening), five days per week, for four weeks. Each session consisted of 30 breathing cycles, resulting in a total of 60 cycles per day. Prior to training, the device resistance was calibrated to 40% of each participant's maximal inspiratory pressure (MIP), as reported by Çelikel et al. (2025) to promote increases in muscle size and thickness. MIP was reassessed weekly and resistance was
CONTROL
NO INTERVENTIONThe research group (Control Group (CG) (n:13)
Interventions
The POWERbreathe® device is a pressure-threshold IMT device that provides resistance during inhalation. The user breathes in through a mouthpiece against an adjustable spring-loaded valve, which opens only when the inspiratory pressure exceeds the set threshold, thereby strengthening the inspiratory muscles over time. Following a one-week familiarization period, the IMT protocol was performed twice daily (morning and evening), five days per week, for four weeks. Each session consisted of 30 breathing cycles, resulting in a total of 60 cycles per day. Prior to training, the device resistance was calibrated to 40% of each participant's maximal inspiratory pressure (MIP), as reported by Çelikel et al. (2025) to promote increases in muscle size and thickness. MIP was reassessed weekly and resistance was increased by 10%; progression was paused if participants experienced excessive strain.
Eligibility Criteria
You may qualify if:
- were defined as women aged 60-80 years (post-menopausal), who were independent in activities of daily living,
- demonstrated adequate cognitive function to follow instructions,
- had no musculoskeletal injury within the previous six months,
- were non-smokers,
- had routine thoracic or abdominal CT images obtained for clinical indications and used in this study.
You may not qualify if:
- included having uncontrolled cardiovascular or pulmonary disease such as heart failure or COPD/asthma exacerbation,
- uncontrolled hypertension, diagnosed chronic liver disease,
- acute respiratory infection within the last four weeks,
- participation in structured respiratory or resistance training within the last six months,
- recent thoracoabdominal surgery or hernia, use of medications known to affect muscle or liver metabolism such as systemic corticosteroids, anabolic agents, or hepatotoxic drugs,
- severe orthopedic or neurological conditions limiting mobility, or refusal to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gumushane Univetsity
Kelkit, Gümüşhane Province, 29600, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- ASSOC. PROF.
Study Record Dates
First Submitted
August 28, 2025
First Posted
September 11, 2025
Study Start
June 5, 2025
Primary Completion
July 15, 2025
Study Completion
August 5, 2025
Last Updated
September 18, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF